Effectivity of P1821, a Novel Tongue Strengthening and Endurance Enhancing Speech Flow Exercise
1 other identifier
interventional
100
1 country
1
Brief Summary
The P1821 initiative constitutes an innovative intervention specifically engineered to enhance tongue muscular strength and endurance. The primary objective of this research study is to ascertain whether the integration of a proactive tongue strengthening exercise regimen, utilizing a Non-Significant Risk (NSR) Device, contributes to an observable improvement in speech fluency.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jan 2028
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 18, 2026
CompletedFirst Posted
Study publicly available on registry
July 22, 2026
CompletedStudy Start
First participant enrolled
January 1, 2028
ExpectedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2029
Study Completion
Last participant's last visit for all outcomes
January 1, 2030
July 22, 2026
July 1, 2026
1 year
July 18, 2026
July 18, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
P1821
The primary key performance indicator will be the proportion of study participants who demonstrate statistically significant and measurable improvements in their speaking ability following the completion of the two-week treatment protocol within P1821. This metric is crucial for evaluating the efficacy of the intervention and will be assessed through standardized linguistic and speech pathology evaluations.
From enrollment to the end of treatment at 2 weeks.
P1821
Compare the number of participants experiencing treatment-related adverse events versus those with positive treatment outcomes.
From enrollment to the end of treatment at 2 weeks.
Study Arms (1)
P1821 #1
EXPERIMENTALP1821 interventions are administered once daily over a period of fourteen days.
Interventions
The P1821 intervention is distinguished by its independence from pharmaceutical agents and electronic devices. Its foundational mechanism is predicated exclusively on the physiological principles of muscle resistance training, thereby offering a non-pharmacological and non-invasive therapeutic approach.
Eligibility Criteria
You may qualify if:
- Can read and write
- Willing and able to follow the requirements of the protocol
You may not qualify if:
- Previously seen and treated by speech and language pathologist for dysphagia or dysarthria for non-head and neck cancer causes
- Medical instability, restlessness, or other factors that would compromise data acquisition
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Dream Video LLClead
- Dream Holdings Researchcollaborator
Study Sites (1)
N/A - Remote Study
Naples, Florida, 34119, United States
Related Publications (8)
Binger C, Ragsdale J, Bustos A. Language Sampling for Preschoolers With Severe Speech Impairments. Am J Speech Lang Pathol. 2016 Nov 1;25(4):493-507. doi: 10.1044/2016_AJSLP-15-0100.
PMID: 27552110BACKGROUNDPotter NL, Nievergelt Y, VanDam M. Tongue Strength in Children With and Without Speech Sound Disorders. Am J Speech Lang Pathol. 2019 May 27;28(2):612-622. doi: 10.1044/2018_AJSLP-18-0023. Epub 2019 Feb 28.
PMID: 31136240BACKGROUNDLalakea ML, Messner AH. Ankyloglossia: the adolescent and adult perspective. Otolaryngol Head Neck Surg. 2003 May;128(5):746-52. doi: 10.1016/S0194-59980300258-4.
PMID: 12748571BACKGROUNDWang J, Yang X, Hao S, Wang Y. The effect of ankyloglossia and tongue-tie division on speech articulation: A systematic review. Int J Paediatr Dent. 2022 Mar;32(2):144-156. doi: 10.1111/ipd.12802. Epub 2021 May 22.
PMID: 33964037BACKGROUNDBelmehdi A, Harti KE, Wady WE. Ankyloglossia as an oral functional problem and its surgical management. Dent Med Probl. 2018 Apr-Jun;55(2):213-216. doi: 10.17219/dmp/85708.
PMID: 30152627BACKGROUNDWei EX, Tunkel D, Boss E, Walsh J. Ankyloglossia: Update on Trends in Diagnosis and Management in the United States, 2012-2016. Otolaryngol Head Neck Surg. 2020 Nov;163(5):1029-1031. doi: 10.1177/0194599820925415. Epub 2020 May 19.
PMID: 32427523BACKGROUNDSuter VG, Bornstein MM. Ankyloglossia: facts and myths in diagnosis and treatment. J Periodontol. 2009 Aug;80(8):1204-19. doi: 10.1902/jop.2009.090086.
PMID: 19656020BACKGROUNDWalsh J, Tunkel D. Diagnosis and Treatment of Ankyloglossia in Newborns and Infants: A Review. JAMA Otolaryngol Head Neck Surg. 2017 Oct 1;143(10):1032-1039. doi: 10.1001/jamaoto.2017.0948.
PMID: 28715533BACKGROUND
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
July 18, 2026
First Posted
July 22, 2026
Study Start (Estimated)
January 1, 2028
Primary Completion (Estimated)
January 1, 2029
Study Completion (Estimated)
January 1, 2030
Last Updated
July 22, 2026
Record last verified: 2026-07
Data Sharing
- IPD Sharing
- Will not share